IA
GERM

IFP Advisors’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

IFP Advisors’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$3.83K – 4697
2024
Q3 		$3.83K Hold
200
– – ﹤0.01% 2751
2024
Q2 		$3.64K Sell
200
-200
-50% -$3.66K ﹤0.01% 2661
2024
Q1 		$7.44K Buy
400
+200
+100% +$3.72K ﹤0.01% 2335
2023
Q4 		$3.91K Hold
200
– – ﹤0.01% 2498
2023
Q3 		$3.58K Hold
200
– – ﹤0.01% 2639
2023
Q2 		$4.12K Hold
200
– – ﹤0.01% 2611
2023
Q1 		$5.03K Hold
200
– – ﹤0.01% 2561
2022
Q4 		$5K Hold
200
– – ﹤0.01% 3833
2022
Q3 		$5K Hold
200
– – ﹤0.01% 4074
2022
Q2 		$5K Hold
200
– – ﹤0.01% 3844
2022
Q1 		$5K Buy
+200
New +$5.63K ﹤0.01% 3844

IFP Advisors's GERM Position: Q4 2024 in Review

IFP Advisors sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q4 2024, closing a stake of 200 shares — an estimated $3.83K sold.

IFP Advisors first reported a position in GERM in Q1 2022 and held it in 11 quarters. The position peaked at $7.44K in Q1 2024. 0 funds tracked by Wall St. Rank hold GERM as of Q4 2024.

  • IFP Advisors reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q4 2024 after selling out during the quarter.
  • IFP Advisors sold 200 Amplify Treatments, Testing and Advancements ETF shares in Q4 2024, an estimated $3.83K.
  • IFP Advisors first reported a position in Amplify Treatments, Testing and Advancements ETF in Q1 2022 and held it in 11 quarters.
  • IFP Advisors's Amplify Treatments, Testing and Advancements ETF position peaked at $7.44K in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q4 2024.

Based on IFP Advisors's 13F filing for Q4 2024, filed 4 Feb 2025.